UPDATE 1-U.S. FDA panel backs approval of Novo Nordisk diabetes drug
October 18, 2017 at 16:39 PM EDT
WASHINGTON, Oct 18 (Reuters) - Novo Nordisk A/S's new diabetes drug semaglutide is effective, reasonably safe and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.
